News Eurocine Vaccines AB

Equities

EUCI

SE0015382155

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-05-19 pm EDT			5-day change	1st Jan Change
0.05 ^SEK	+1.63%		+5.93%	+8.70%

Feb. 28	Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
Feb. 15	Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 28	CI
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 15-FEB-2024.	Feb. 14	CI
Correction - Eurocine Vaccines discloses interim report for July - September 2023	Nov. 28	AQ
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 28	CI
Eurocine Vaccines discloses interim report for Juli - September 2023	Nov. 28	AQ
Eurocine Vaccines AB Reports Earnings Results for the Fourth Quarter Ended June 30, 2023	23-08-30	CI
Eurocine Vaccines AB Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Eurocine Vaccines discloses interim report for July 2022 - March 2023	23-05-24	AQ
Eurocine Vaccines AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-24	CI
Eurocine Vaccines Wins SEK300,000 Grant from Merck KGaA	23-05-04	MT
Certain Shares of Eurocine Vaccines AB are subject to a Lock-Up Agreement Ending on 17-APR-2023.	23-04-16	CI
Eurocine Vaccines discloses half-year report for July - December 2022	23-02-28	AQ
Eurocine Vaccines AB Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-28	CI
Eurocine Vaccines to Develop Chlamydia Vaccine Candidate Using mRNA	23-01-18	MT
Eurocine Vaccines decides to develop mRNA-based vaccine candidate against chlamydia	23-01-17	AQ
Eurocine Vaccines AB Decides to Develop mRNA-Based Vaccine Candidate Against Chlamydia	23-01-17	CI
Outstanding results for Eurocine Vaccines' mRNA based HSV-2 candidate	22-12-21	AQ
Eurocine Vaccines : Outstanding results for Eurocine Vaccines´ mRNA based HSV-2 candidate	22-12-20	PU
Eurocine Vaccines AB Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-28	CI
Eurocine Vaccines Receives Patent Coverage In South Korea For Vaccine Candidate	22-08-30	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Eurocine Vaccines AB

Equities

EUCI

SE0015382155

Summary

Filters